The future of cannabinoid-based medicine hinges on such innovations which is: the ability to produce cannabinoids identical to those found in nature in a safe, consistent and economical fashion to advance cannabis-based drug development.
The future of cannabinoid-based medicine hinges on such innovations which is: the ability to produce cannabinoids identical to those found in nature in a safe, consistent and economical fashion to advance cannabis-based drug development.
Through building a diversified holding base, SinglePoint, Inc. (OTC: SING) has developed from a full-service mobile technology provider to a publicly traded holding company, and its SingleSeed subsidiary is working to solve an issue that is currently plaguing legal cannabis businesses: a lack of traditional banking options.
InMed Pharmaceuticals is making bacteria-bred cannabinoids “identical to those found in nature,” sans chemicals or even cannabis.
SinglePoint (OTC: SING) continues to pursue strategic opportunities to widen its foothold in the cannabis industry while hedging itself against potential risks regarding the legality of marijuana.
India Globalization Capital, Inc. (NYSE MKT: IGC) is racing ahead with its preparation of medical trials for four drug candidates that treat a variety of debilitating conditions.
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), through its proprietary technology for delivering bioactive compounds in lipid formulations, offers licensed partners the ability to include cannabidiol (CBD) in a variety of ingestible products appropriate for medical patients and recreational users alike.
Singlepoint, Inc. (OTC: SING) welcomed the recent request to the Financial Crimes Enforcement Network (FINCEN), by 10 senators, for further guidance ‘to financial institutions on their ability to provide services, specifically to indirect businesses that do nothing more than provide services to the state-sanctioned marijuana industry’.
Before the opening bell, Singlepoint, Inc. (OTC: SING) kicked off the new year by voicing its support for an ongoing congressional push calling for banking reform as it relates to the burgeoning legal cannabis industry.
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product.
Algae Dynamics Corp. (OTCQB: ADYNF), a Canadian company focused on the development of proprietary research and products derived from cannabis and hemp oils, has begun a collaborative relationship with one neuroscientist who is looking deep within the brain for answers to some of the world’s most pressing mental health problems.
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) achieved working capital of $43 million from multiple financings, including private placements and strategic partnerships, during the six months ended June 30, 2017.
Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its retention of Biopsy, LLC, managed by bestselling author Chris J. Snook, to provide leadership in growth and e-commerce.
Singlepoint, Inc. (OTC: SING), a publicly traded holding company, offers payment solutions to the cannabis industry through its SingleSeed subsidiary.
Diamond CBD Sales, a subsidiary of PotNetwork Holding, Inc. (OTC: POTN), attained more than $200,000 in sales at the Big Industry Trade Show in New York on August 10-11.
Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available.